(2026). Development and validation of a cuproptosis-immune prognostic signature for risk stratification and personalized therapy in cutaneous melanoma. Discover Oncology.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Development and Validation of a Cuproptosis-immune Prognostic Signature for Risk Stratification and Personalized Therapy in Cutaneous Melanoma."
Discover Oncology 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Development and Validation of a Cuproptosis-immune Prognostic Signature for Risk Stratification and Personalized Therapy in Cutaneous Melanoma."
Discover Oncology, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.